AbbVie and Allergan sue Galderma over redesigned Restylane syringe shape

AbbVie and Allergan have filed a patent-infringement lawsuit against Galderma in the US District Court for the Northern District of Texas, a move that highlights how fiercely major manufacturers guard the tactile and visual branding of their delivery systems. Filed on July 23, 2026, under case number 3:26-cv-02420, the complaint alleges that Galderma's redesigned Restylane syringe infringes on five US design patents protecting the look of Allergan's Juvéderm syringes. The litigation focuses entirely on ornamental features, specifically the finger grips, plunger head shape, and syringe barrel contours, rather than product safety or formulation. The plaintiffs claim Galderma "made a calculated decision" to mimic the Juvéderm design. For practice owners, this legal battle does not impact the safety, efficacy, or immediate availability of either Restylane or Juvéderm in your trays. However, it serves as a reminder of how heavily ergonomics and device design influence brand loyalty and injector preference. While supply chains remain unaffected for now, clinicians should monitor the case, as a ruling against Galderma could force another redesign of the Restylane delivery system, requiring injectors to adapt to yet another change in hand-feel and plunger resistance during administration.

Source: Life Sciences Intellectual Property Review, https://www.lifesciencesipreview.com/news/abbvie-allergan-takes-on-swiss-aesthetics-rival-over-syringe-design-5142